Ir para o conteúdo principal

United States Últimas notícias

Todas as matérias desta categoria, das mais recentes às mais antigas.

Bloomberg

US Iran Tensions Fuel Market Uncertainty

Democratic strategist Adam Hodge from Bully Pulpit International joins Bloomberg Open Interest to break down rising US tensions with Iran, calling out mixed messaging from the White House, Congress's absence during the crisis, and the growing economic fallout. With oil prices climbing and no clear endgame, he talks about what comes next for markets and global stability.

Leia mais: US Iran Tensions Fuel Market Uncertainty
Grafa

Scienture revenue rallies 216% in 2025 on Arbli launch and record margin expansion

Scienture (NASDAQ:SCNX), a specialty pharmaceutical company focused on developing and commercializing innovative therapies for underserved patient populations, today reported its financial results for the full year ended December 31, 2025.

Leia mais: Scienture revenue rallies 216% in 2025 on Arbli launch and record margin expansion
Bloomberg

BinGhatti: UAE Property Market Behavior Fairly Stable

Property developers in the UAE have held calls with investors to allay concerns over a potential liquidity crunch after their bonds slipped into distressed territory. Katralnada BinGhatti, CEO & Managing Director of BinGhatti Holding spoke to Bloomberg's Horizons Middle East and Africa anchor Joumanna Bercetche about the plans they're putting in place to deal with the regional situation.

Leia mais: BinGhatti: UAE Property Market Behavior Fairly Stable
Bloomberg

Roebuck: US on Escalation Track in Iran

President Trump says Iran has given the US most of the 15 demands to end the war even as it remains unclear whether either side is negotiating. William Roebuck, Executive Vice President at the Arab Gulf States Institute and a former US Ambassador to Bahrain spoke to Bloomberg's Horizons Middle East and Africa anchor Joumanna Bercetche about the US ground troops in the Mideast.

Leia mais: Roebuck: US on Escalation Track in Iran
Grafa

Reviva Pharmaceuticals narrows path to Brilaroxazine FDA submission with 2026 Phase 3 launch

Reviva Pharmaceuticals Holdings (NASDAQ:RVPH), a clinical-stage pharmaceutical company developing next-generation therapies for central nervous system (CNS) disorders, today announced its financial results and corporate updates for the full year ended December 31, 2025.

Leia mais: Reviva Pharmaceuticals narrows path to Brilaroxazine FDA submission with 2026 Phase 3 launch